This is a Phase 3, randomized, double-masked, placebo-controlled study designed to determine
the effectiveness of myo-Inositol 5% Injection to increase the incidence of survival without
severe Retinopathy of Prematurity (ROP) through acute/final ROP determination up to 55 weeks
postmenstrual age (PMA) in premature infants <28 0/7 weeks' gestation.
Phase:
Phase 3
Details
Lead Sponsor:
NICHD Neonatal Research Network
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Eye Institute (NEI)